Greenwich Lifesciences, Inc.

This large Phase 3 trial is testing whether an immunotherapy called GLSI-100 can prevent breast cancer from returning in patients at high risk for recurrence. The study involves 750 people who have already finished their standard breast cancer treatments but still have a high cha…